---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-026752"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2022-09-26T23:59:59+00:00"
generated_at: "2026-06-23T07:31:46.621564+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Anebulo reports positive interim Phase 2 data for ANEB-001 in acute cannabinoid intoxication

## Summary
- Part B: 21mg THC challenge; 10mg or 30mg ANEB-001 significantly reduced VAS feeling high (p<0.001), improved alertness (p<0.01), and reduced body sway (p<0.01) vs placebo.
- Placebo group: 100% of subjects met VAS threshold for feeling high; only 1 subject per active dose group met threshold.
- Safety: adverse events mild/transient except two moderate dizziness cases in Cohort 1 likely THC-attributable.
- Company continuing Part B, enrolling third cohort; collaborating with FDA MIDD group on PK/PD model to optimize dosing for ACI.

## SEC filing metadata
- accession: 0001493152-22-026752
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2022-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315222026752/0001493152-22-026752-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315222026752/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-026752
- JSON: https://secwatch.observer/filing/0001493152-22-026752.json
- Plain text: https://secwatch.observer/filing/0001493152-22-026752.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.